Chai Discovery, an applied AI research lab that reprograms the interactions between biochemical molecules, announced a $130 million Series B funding round, bringing its valuation to $1.3 billion. The round, led by Oak HC/FT and General Catalyst, brings Chai Discovery’s total funding to more than $225 million.
“Our latest models can design molecules that have properties we’d want from actual drugs, and tackle challenging targets that have been out of reach,” Josh Meier, Chai Discovery’s co-founder and CEO, said in a statement. “These models will unleash a new wave of first-in-class and best-in-class therapeutics, and the early adopters in pharma will be the big winners.”
The company’s Series B follows closely after its $70 million Series A. Chai Discovery plans to invest the round in accelerating R&D and expanding its commercialization efforts. Its goal is to develop a “computer-aided design suite” for molecules.
